SUNCIST: A Study of Calmangafodipir in Healthy Japanese and Caucasian Subjects

NCT03430999 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Chemotherapy Induced Peripheral Neuropathy (CIPN)

Interventions

DRUG: Calmangafodipir
DRUG: Placebo

Sponsor

Egetis Therapeutics